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Abstract 
Background: In Japan, postmarketing surveillance (PMS) studies are required for newly approved drug products to 
further collect safety information in clinical settings. “PMS study” is a general term encompassing both postmarketing 
observational (PMO) studies and postmarketing intervention studies for re-examination. Each PMS study is conducted 
under contracts between the pharmaceutical company and medical institutions in accordance with Good Postmar-
keting Study Practice. It has been reported that the safety information collected postmarketing is limited because 
of underreporting. The objective of this investigation was to identify differences among profiles of the drug product 
safety information collected through intervention studies and observational studies before and after approval. Our 
study addressed whether the issue of underreporting, generally considered as associated with observational studies, 
occurs in PMO studies for re-examination. In addition, we considered potential causes of such underreporting.
Results: The overall adverse reaction rate was lower in PMO studies than in intervention studies before approval in 
almost all cases. The adverse reaction rate in intervention studies exhibited similar profiles regardless of whether they 
were conducted prior to or following approval. In addition, we found that one reason for a lower adverse reaction rate 
in PMO studies was that the number of reports of adverse reactions that had occurred frequently prior to approval 
decreased postmarketing.
Conclusions: Underreporting was observed even in PMO studies for re-examination under the Japanese regulation. 
Although it was suggested that expected and common adverse reactions were more likely to be subject to underre-
porting, further investigation is warranted to explore the reasons for the under-reporting in PMO studies.
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Background
Information on drug product safety is collected begin-
ning before marketing approval and continuing after 
approval. Before approval, highly accurate information 
can be obtained through intervention studies (phase 
1, 2, and 3 clinical trials) conducted in specific popula-
tions. After approval, safety information is primarily 
collected based on spontaneous reports and/or observa-
tional studies performed in daily medical examinations 
(Banerjee et al. 2013). Generally, in intervention studies, 
randomized, double-blind, comparative studies intended 
to verify hypotheses are conducted to obtain results with 
a high level of evidence. In contrast, in observational 
studies—sometimes beneficial for forming hypotheses 
because of potentially large sample numbers—control 
groups are virtually never included and the level of evi-
dence of the results, therefore, is not very high.
Clinical studies prior to approval are usually con-
ducted under a limited range of conditions, which has 
been referred to as the “5 toos” (too few, too simple, too 
narrow, too median-aged and too brief ) (Rogers 1987) 
making it difficult to obtain all necessary safety infor-
mation solely with such studies. In recent years, there 
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has been more internationalization of clinical drug 
development programs. This has resulted in approval 
in Japan of new drug products for which only limited 
safety information on Japanese patients had been col-
lected and evaluated (Iwasaki et  al. 2012). Therefore, 
“collection of safety information at the postmarket-
ing stage especially through observational studies” 
is becoming increasingly important. However, it has 
been reported that safety information collected post-
marketing is limited because of underreporting (Hazell 
and Saad 2006; Macdougall et  al. 2008). It is generally 
understood that expected and non-serious adverse 
reactions are more likely to be underreported. Bäck-
ström et al. (2004) showed that at least 80 % of adverse 
reactions occurring postmarketing are not reported. 
Lopez-Gonzalez et al. (2009) attributed underreporting 
to such causes as “ignorance/preconceptions” (a belief 
that only serious adverse reactions need to be reported) 
and a “sense of security” (a feeling that only safe drug 
products are allowed onto the market).
Regarding regulation of postmarketing, in the Euro-
pean Union (EU) postmarketing safety monitoring 
systems have been strengthened, including by pharma-
covigilance legislation implemented in 2012 (European 
Union 2011). In Japan as well, a guideline for a drug risk 
management plan (RMP) was issued in 2012 and, since 
April 2013, companies applying for marketing approval 
have been required to submit a RMP that contains post-
marketing pharmacovigilance and risk minimization 
plans. These plans must account for risks, such as impor-
tant identified/potential risks and missing information of 
the drug product (Risk Management Plan 2012). Japan 
is currently in the process of developing a new pharma-
covigilance system.
In Japan, postmarketing surveillance (PMS) studies are 
required for newly approved drug products to ensure 
further collection of safety information in clinical set-
tings. “PMS study” is a general term that encompasses 
both postmarketing observational (PMO) studies for re-
examination, treatment outcome studies and postmar-
keting intervention (PMI) studies for re-examination, 
also known as phase 4 clinical studies. Each PMS study 
is conducted under contracts between the pharmaceuti-
cal company and medical institutions in accordance with 
Good Post-marketing Study Practice (GPSP) Ministe-
rial Ordinance (MHLW Ministerial Ordinance No. 171, 
issued December 20, 2004).
For most new drug products or existing drug products 
for which additional indications have been approved, 
PMO studies for re-examination are routinely conducted 
to collect safety information after approval. “Re-examina-
tion” is a regulatory system specifying safety and efficacy 
testing of marketed new drugs within a certain period 
of time (normally 8  years) after approval to re-confirm 
drug effectiveness in clinical settings. This effectiveness 
is based primarily on the results of PMO studies for re-
examination and spontaneous reports of adverse reac-
tions. Because of this system, many PMO studies for 
re-examination are conducted postmarketing and are 
sponsored by pharmaceutical companies. However, most 
of these PMO studies for re-examination are conducted 
in a target sample size of 3000 patients without a control 
group. This sample size is regarded as sufficient to detect, 
with a 95 % probability, relatively rare adverse reactions 
occurring in about 1 out of 1000 patients (an incidence 
of 0.1 %) (Iwasaki et al. 2012). Neither the sample size nor 
the study purpose takes into account the characteristics 
of the safety information that was collected prior to drug 
product approval. For this reason, the safety information 
obtained from PMO studies for re-examination are sel-
dom used for postmarketing safety actions such as revi-
sion of package inserts (Kanmuri and Narukawa 2014).
Conversely, in PMI studies for re-examination, the 
objectives of which may include collecting additional 
information not collected in the clinical studies con-
ducted prior to approval, control groups are established 
and randomization is often performed. However, such 
PMI studies for re-examination are conducted only occa-
sionally and for a limited number of new drugs. In fact, 
according to the ClinicalTrials.gov registry, there are few 
industry-funded PMI studies for re-examination being 
conducted in Japan.
Information collected in PMO studies for re-exami-
nation is structured, unlike that in spontaneous reports, 
and study plans are submitted in advance to the Min-
istry of Health, Labour and Welfare. In addition, PMO 
studies are conducted by medical professionals under 
contracts signed between the pharmaceutical compa-
nies and medical institutions. Therefore, PMO studies 
for re-examination are expected to collect safety data 
with higher quality and credibility compared with data 
collected under other observational studies. Nonethe-
less, in a questionnaire survey regarding PMO studies 
for re-examination administered to medical representa-
tives of pharmaceutical companies, the representatives 
reported that non-serious and expected adverse reac-
tions in particular are often underreported (Watanabe 
and Narukawa 2015). It was also reported that in PMO 
studies for re-examination, data collection is performed 
primarily by the investigators themselves with little sup-
port from other departments (Watanabe and Narukawa 
2014).
With this as background, we focused on safety data 
collected in PMO studies in Japan, which are routinely 
conducted under the framework of the pharmaceutical 
regulation known as re-examination. The objective of our 
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investigation was to identify differences in profiles of the 
drug product safety information collected through inter-
vention studies and observational studies, and before and 
after approval. Our study addressed whether the issue of 
underreporting, generally considered as associated with 
observational studies, occurs in PMO studies for re-




When a re-examination is completed for a product, its 
package insert is revised based on the results of PMS 
studies. This revision is considered a “milestone revision,” 
making it possible to comprehensively identify the post-
marketing safety information that was collected, primar-
ily by the pharmaceutical company.
We searched the package inserts of drug products for 
which re-examinations were completed between Janu-
ary 2009 and December 2014. Among them, we identi-
fied package inserts for 189 drug products that included 
information categorized as “adverse reaction rate in clini-
cal studies for new drug application (NDA)” and “adverse 
reaction rate in PMS studies” and used these inserts for 
our investigation. We also extracted information listed 
under “adverse reaction rate in PMI studies for re-exam-
ination,” either from the package insert or the re-exami-
nation report of the product. We used the package insert 
search tool of the Pharmaceuticals and Medical Devices 
Agency to obtain package inserts, re-examination reports 
and drug product interview forms for the drug products 
included in our analysis.
Information extraction and tabulation
Comparison of overall adverse reaction rates before versus 
after approval
From the package inserts of the aforementioned 189 drug 
products, we extracted the overall adverse reaction rate 
in clinical studies for NDA (ARR-NDA) and the overall 
adverse reaction rate in PMO studies for re-examination 
(ARR-PMO) and prepared a scatter plot. Furthermore, 
for drug products for which PMI studies for re-examina-
tion were conducted following approval, we extracted the 
overall adverse reaction rates in PMI studies for re-exam-
ination (ARR-PMI) and prepared a scatter plot against 
those for the ARR-NDA.
The number of ARR-NDA and ARR-PMO were calcu-
lated in the following way.
  • ARR-NDA (%)  =  total number of all adverse reac-
tions/total number of subjects in clinical studies for 
NDA
  • ARR-PMO (%)  =  total number of all adverse reac-
tions/total number of subjects in PMO studies for re-
examination.
Comparison of incidence rates of the most common adverse 
reactions in clinical studies for NDA versus in postmarketing 
observational studies for re‑examination
For each of the 189 drug products, we specified the most 
common adverse reaction in clinical studies for NDA 
based on their package inserts and then calculated the 
difference between this incidence rate and that obtained 
in PMO studies for re-examination. We calculated the 
difference between overall adverse reactions data from 
ARR-NDA and ARR-PMO and prepared a scatter plot. 
Each adverse reaction for the investigation was classi-
fied by the system organ class of the Medical Dictionary 
for Regulatory Activities (MedDRA/J Ver.19.0J), and also 
categorized as serious or non-serious based on the pres-
ence or absence in the section of “serious adverse reac-
tions” of the package insert.
Results
We identified 189 drug products for which the infor-
mation of adverse reaction rates both in clinical stud-
ies for NDA and in PMS studies were available. Among 
these, both the ARR-NDA and ARR-PMO were avail-
able for 176 products and both the ARR-NDA and ARR-
PMI were available for 45 products. For 162 of the drug 
products, it was possible to compare incidence rate of 
the most common adverse reaction obtained in clinical 
studies for NDA to that obtained in PMO studies for re-
examination. Characteristics of these products are shown 
in Table 1.
Comparison of overall adverse reaction rates before versus 
after approval
First, we compared the ARR-NDA and ARR-PMO. We 
defined a drug product whose package inserts contained 
both the ARR-NDA and ARR-PMO for an individual 
indication as 1 set and obtained 206 sets of such informa-
tion from 176 products (Table 1). We prepared a scatter 
plot with the ARR-NDA along the vertical axis and the 
ARR-PMO along the horizontal axis (Fig.  1). This plot 
showed that the overall adverse reaction rates in clinical 
studies for NDA were higher than those in PMO studies 
for re-examination in 88.3 % of the information sets (182 
of 206 sets).
We next compared the ARR-NDA and ARR-PMI. We 
extracted the adverse reaction rates in PMI studies for 
re-examination from the package insert or the re-exam-
ination reports of 189 drug products, obtaining 48 sets of 
ARR-NDA and ARR-PMI data for 45 products (Table 1). 
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We prepared a scatter plot with the ARR-NDA along the 
vertical axis and the ARR-PMI along the horizontal axis 
(Fig.  2). This plot showed that the overall adverse reac-
tion rates in clinical studies for NDA were higher than 
those in PMI studies for re-examination in 56.3 % of the 
information sets (27 of 48 sets).
Difference of incidence rates of the most common adverse 
reaction in clinical studies for NDA versus in postmarketing 
observational studies for re‑examination
We prepared a scatter plot for the 192 sets of data 
obtained for 162 drug products as follows: differ-
ences between the incidence rates of the most com-
mon adverse reaction in clinical studies for NDA and 
those in PMO studies for re-examination on the hori-
zontal axis, differences between the overall adverse 
reactions in ARR-NDA and those in ARR-PMO on 
the vertical axis (Fig.  3). This plot showed that the 
two variables were correlated (Spearman’s r = 0.800, 
p  <  0.0001). Each adverse reaction was classi-
fied by the MedDRA system organ class (Table  2). 
Serious adverse reactions were observed more often 
in “metabolism and nutrition disorders”, “vascular 
disorders” and “cardiac disorders”.
Discussion
Of the 189 drug products analyzed in our study, we 
focused on those package inserts that had the informa-
tion categorized as “adverse reaction rate in PMO studies 
for re-examination,” and compared these to information 
described as “adverse reaction rate in clinical studies for 
NDA.” We found that, in 88.3 % of the 206 sets of infor-
mation obtained for 176 drug products (182 of 206 sets), 
the adverse reaction rate in clinical studies for NDA was 
higher than that in PMO studies for re-examination 
(Fig. 1). On the contrary, as shown in Fig. 2, the adverse 
reaction rate in PMI studies for re-examination, which 
were conducted postmarketing, exhibited a profile simi-
lar to that found in clinical studies for NDA. Further-
more, as shown in Fig.  3, the proportion by which the 
incidence rate of the most common adverse reaction 
in clinical studies for NDA decreased postmarketing 
Table 1 Characteristics of  the products investigated (176 drug products for Fig. 1, 45 drug products for Fig. 2 and 162 
drug products for Fig. 3)
(A) Drug products for which both the adverse reaction rate in clinical studies for NDA and in postmarketing observational (PMO) studies were available (Fig. 1)
(B) Drug products for which both the adverse reaction rate in clinical studies for NDA and in postmarketing intervention (PMI) studies were available (Fig. 2)
(C) Drug products for which the incidence rate of the most common adverse reaction in clinical studies for NDA and in PMO studies for re-examination were available 
(Fig. 3)
(A) 176 drug products (B) 45 drug products (C) 162 drug products
Therapeutic group
 A—alimentary tract and metabolism 18 8 17
 B—blood and blood-forming organs 9 3 8
 C—cardiovascular system 20 3 20
 D—dermatologicals 6 3 5
 G—genitourinary system and sex hormones 13 1 13
 H—systemic hormonal preparations, excluding sex hormones and 
insulins
7 1 6
 J—anti-infectives for systemic use 25 5 23
 L—anti-neoplastic and immunomodulating agents 10 3 10
 M—musculoskeletal system 6 3 6
 N—nervous system 24 8 23
 P—anti-parasitic products, insecticides, and repellents 2 0 1
 R—respiratory system 15 4 10
 S—sensory organs 6 1 6
 V—various 15 2 14
Re-examination dates
 January 2009 to December 2009 45 6 42
 January 2010 to December 2010 44 13 42
 January 2011 to December 2011 30 9 27
 January 2012 to December 2012 21 5 20
 January 2013 to December 2013 19 8 16
 January 2014 to December 2014 17 4 15
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correlated to the proportion by which the incidence rate 
of the overall adverse reactions decreased postmarketing.
Results of this study indicated that, even in observa-
tional studies controlled by the pharmaceutical regula-
tions in Japan—that is, PMOs—the adverse reaction rate 
was lower than that in intervention studies in most cases. 
In contrast, intervention studies conducted either prior 
to or after approval exhibited similar profiles in terms 
of adverse reaction rate. In addition, our findings sug-
gest that one reason for a lower adverse reaction rate in 
PMO studies was that the number of reports of adverse 
reactions that had occurred frequently prior to approval 
decreased postmarketing; in other words, expected and 
common adverse reactions and non-serious adverse reac-
tions were likely to be subject to underreporting.
In Japan, PMI studies for re-examination and clini-
cal studies for NDA are conducted under Good Clinical 
Practice (GCP) Ministerial Ordinance (MHLW Ministe-
rial Ordinance No. 28, issued March 27, 1997). However, 
GCP does not apply to PMO studies for re-examination 
even though these provide most of the data in the re-

















Fig. 1 Scatter plot of the adverse reaction rate in clinical studies for 
NDA (ARR-NDA) and the adverse reaction rate in PMO studies for 
re-examination (ARR-PMO) (176 drug products, 206 sets). Vertical axis 
ARR-NDA adverse reaction rate in clinical studies for NDA. Horizontal 


















Fig. 2 Scatter plot of the adverse reaction rate in clinical studies for 
NDA (ARR-NDA) and the adverse reaction rate in PMI studies (ARR-
PMI) (45 drug products, 48 sets). Vertical axis ARR-NDA adverse reac-
tion rate in clinical studies for NDA. Horizontal axis ARR-PMI adverse 























Difference of incidence rate of the most common adverse reaction
in clinical studies for NDA and that in PMO studies for 
reexamination  (%)
Fig. 3 Relationship between: the difference of incidence rate of the 
most common adverse reaction in clinical studies for NDA and that in 
PMO studies; and the difference of the overall adverse reaction rate in 
clinical studies for NDA and that in PMO studies (162 drug products, 
192 sets). Vertical axis difference of the overall adverse reaction rate in 
clinical studies for NDA and that in PMO studies for re-examination 
(ARR-NDA–ARR-PMO). Horizontal axis difference of incidence rate of the 
most common adverse reaction in clinical studies for NDA and that in 
PMO studies for re-examination
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In a questionnaire survey of physicians about PMO stud-
ies, 32 % of the respondents indicated that they believed 
“there is no scientific validity” and 43  % that “scientific 
validity is not required” of such studies (Japanese Asso-
ciation of Pharmaceutical Medicine 2010). These results 
suggest that low motivation of investigators at par-
ticipating medical institutions also contributes to the 
underreporting.
Hazell and Saad et  al. (2006) showed that the median 
underreporting rate across 37 studies (not including Japa-
nese) was 94 % and the reason for not reporting included 
a lack of time, difficulty in accessing reporting form, etc. 
In Japan, each PMS study is conducted in accordance 
with GPSP. Nevertheless, the results of our investiga-
tion suggest that it is difficult to prevent underreporting 
even in the studies that, unlike spontaneous reports, are 
conducted under contracts signed between pharmaceu-
tical companies and medical institutions as specified by 
regulations.
The limitations of our investigation include the small 
sample size of PMI studies for re-examination compared 
with that of PMO studies. Another limitation is that, in 
our investigation of underreporting, changes in all indi-
vidual adverse reactions were not investigated; we only 
investigated the changes before versus after approval 
in the number of adverse reactions most frequently 
reported prior to approval.
In Japan, to date, the most common studies to col-
lect safety information after drug approval have been 
PMO studies. Now, similar to the situation in the EU and 
United States, a guideline on RMP has existed in Japan 
since 2012. This guideline requires that companies apply-
ing for market approval submit a RMP that contains 
postmarketing pharmacovigilance and risk minimization 
plans, accounting for the potential risks of the drug prod-
uct. In addition, a system allowing direct adverse reaction 
reporting by patients was introduced in March 2012 in 
Japan; patient adverse reaction reporting systems were 
introduced in 1993 in the United States and subsequently 
in Europe, emphasizing the importance of information 
reported directly by patients (Avery et  al. 2011). Fur-
thermore, similar to the Sentinel Initiative in the United 
States, a large-scale (tens of millions of persons) health 
care information database sentinel project was initiated 
in Japan in 2011. Thus, systems for safety information 
surveillance following approval have reached a major 
turning point.
There is a need for increased types of PMS activities, 
including those using large-scale health care informa-
tion databases. One option might be to exclude expected 
and non-serious adverse reactions that have already been 
identified by clinical studies for NDA, and which are 
Table 2 Characteristics of the most common adverse reac-
tion in  clinical studies for  NDA (162 drug products, 192 
sets for Fig. 3)




Blood and lymphatic 
system disorders
1 1
Cardiac disorders 3 0























Psychiatric disorders 0 1










Skin and subcutaneous 
tissue disorders
0 17
Vascular disorders 5 9
for re-examination, PMI studies for re-examination are 
expected to have a level of quality that is equivalent to 
that of clinical studies for NDA and appear to have a sim-
ilar safety profile. But even for PMO studies for re-exam-
ination, it is usually stipulated in study protocols that all 
adverse events (regardless of causality) that occur during 
a specified period following the administration of the 
drug product in question be reported, and there conse-
quently should be no differences in the safety information 
collected between before and after approval. Neverthe-
less, one of the reasons that observational studies have 
a different safety profile than intervention studies con-
ducted before or after approval appears to be the lack of 
a GCP requirement dictating activities, such as monitor-
ing, that ensure reliability. Furthermore, PMO studies for 
re-examination are often so-called “3000-case studies.” 
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more likely to be underreported, from specific pharma-
covigilance activities. For important potential adverse 
reactions, PMI studies should be proactively planned and 
conducted with a control group to identify the degree 
of risks. Conducting PMS studies only in specific medi-
cal institutions with quality systems in place would be 
another potential solution. Through such efforts, post-
marketing safety data might be collected in a better and 
more efficient way to enhance patient safety.
Conclusions
From the present study, it was confirmed that under-
reporting, generally considered as associated with 
observational studies, occurred in PMO studies for re-
examination. Also, it was suggested that expected and 
common adverse reactions were likely to be subject to 
underreporting. Now systems for safety information sur-
veillance following approval have reached a major turn-
ing point in Japan, and we need to seek a better and more 
efficient way to collect postmarketing safety data with 
increased types of PMS activities.
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